| ER | Estrogen receptor |
| HER2 | Human epidermal growth factor receptor 2 |
| CDK | Cyclin-dependent kinase |
| CAK | CDK-activating kinase |
| PFS | Progression-free survival |
| TNBC | Triple-negative breast cancer |
| FDA | Food and Drug Administration |
| RAS | Rat sarcoma |
| MAPK | Mitogen-activated protein kinase |
| RAF | Rapidly accelerated fibrosarcoma |
| MEK | Mitogen-activated protein kinase |
| ERK | Extracellular signal-regulated kinase |
| PDX | Patient-derived xenograft |
| PI3K | Phosphoinositide 3-kinase |
| PIP2 | Phosphatidylinositol (4,5)-bisphosphate |
| PIP3 | Phosphatidylinositol (3,4,5)-trisphosphate |
| PDK | Phosphoinositide-dependent kinase |
| MTORC2 | Mechanistic target of rapamycin complex 2 |
| PTEN | Phosphatase and tensin homolog |
| RTK | Receptor tyrosine kinase |
| JAK-STAT | Janus kinase-signal transducer and activator of transcription |
| FGFR | Fibroblast growth factor receptor |
| EGFR | Epidermal growth factor receptor |
| ROS | Reactive oxygen species |
| HCQ | Hydroxychloroquine |
| ICB | Immune checkpoint blockade |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed cell death-ligand 1 |
| SPOP | Speckle-type POZ protein |
| CXCL | C-X-C motif chemokine ligand |
| NFAT | Nuclear factor of activated T cell |
| HLA | Human leukocyte antigen |
| MHC | Major histocompatibility complex |
| NK cell | Natural killer cell |
| SASP | Senescence-associated secretory phenotype |
| MDM2 | Mouse double minute 2 |
| WD/DDLS | Well-differentiated and dedifferentiated liposarcoma |
| PDLIM7 | PDZ and LIM domain 7 |
| CDH18 | Cadherin 18 |
| FOXM1 | Forkhead box M1 |
| BH3 | Bcl-2 homology 3 |
| BCL-2 | B-cell lymphoma 2 |
| CG | Cardiac glycoside |
| FOXO4 | Forkhead box o4 |
| HSP90 | Heat shock protein 90 |
| AMPKα2 | AMP-activated protein kinase alpha 2 |
| GPX4 | Glutathione peroxidase 4 |
| Rb | Retinoblastoma protein |